Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404174 | 1.00 | GRIK1 (0.51) | GRIK1TRPV1CA12CA1CA7 | |
| SCHEMBL6137306 | 0.83 | MMP2 (0.42) | GRIK1 | |
| SCHEMBL6137308 | 0.83 | MMP2 (0.42) | GRIK1 | |
| SCHEMBL6833386 | 0.82 | MMP2 (0.41) | GRIK1 | |
| SCHEMBL6833383 | 0.82 | MMP2 (0.41) | GRIK1 | |
| SCHEMBL1915710 | 0.77 | CYP3A4 (0.50) | CA12CA1CA7CA14ATM | |
| SCHEMBL1915707 | 0.77 | CYP3A4 (0.50) | CA12CA1CA7CA14ATM | |
| SCHEMBL1915706 | 0.77 | CYP3A4 (0.50) | CA12CA1CA7CA14ATM | |
| SCHEMBL6058619 | 0.76 | GRIN2B (0.44) | GRIK1CA12CA1CA7CA14 | |
| SCHEMBL6058625 | 0.76 | GRIN2B (0.44) | GRIK1CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | claimed |
| JP-2003519133-A | — | — | 2003-06-17 | — | — | JP | claimed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | claimed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | claimed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1373231-B1 | 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1199301-B1 | Olefination process to itaconate and succinate derivatives | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| CN-1349971-A | Olfination method of itaconic acid and succinic acid derivatives | PFIZER (US) | 2002-05-22 | — | — | CN | disclosed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1199301-A1 | Olefination process to itaconate and succinate derivatives | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | GRIK1 4615/4885TRPV1 2823/4885CA12 820/4885 |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, HADHA, OGDH | GRIK1 2395/4885TRPV1 2784/4885CA12 1606/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | GRIK1 4359/4885TRPV1 1944/4885CA12 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.